Similarly, SGLT2 inhibitors have demonstrated significant cardioprotective and renoprotective effects, which are crucial given the increased risk of cardiovascular and renal complications in women with T2DM [29]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.